La-Banyu

Newbouldia laevis stem bark and leaf extracts contain dominant bioactives including Humulene (16.85%), gamma-Terpinene (16.11%), Caryophyllene (7.51%), and flavonoid-rich phenolics (~35% phenolic composition) that exert anti-inflammatory, antioxidant, and antimicrobial effects through free radical scavenging and membrane disruption pathways. Preclinical in vitro data demonstrate antimicrobial minimum inhibitory concentrations (MIC) as low as 1.563 mg/ml against Escherichia coli and antioxidant activity confirmed by ferric-reducing assays, though no human clinical trials have been completed to quantify therapeutic effect sizes in epilepsy or convulsion management.

Origin & History

Newbouldia laevis is a medium-sized evergreen tree native to tropical West and Central Africa, distributed widely across countries including Nigeria, Benin, Cameroon, Ghana, and Côte d'Ivoire, where it thrives in humid lowland forests, forest margins, and savanna transition zones. The tree grows readily in well-drained lateritic soils at low to mid elevations and is often cultivated near homesteads and sacred sites due to its cultural and medicinal importance. All parts of the plant—stem bark, leaves, roots, and flowers—are harvested for traditional medicinal use, with the tree regarded as a boundary marker and symbol of life in many West African communities.

Historical & Cultural Context

Newbouldia laevis holds profound cultural significance across West and Central Africa, commonly known by regional names including 'Akoko' in Yoruba (Nigeria), 'Fertility Tree,' and 'La-Banyu' in other regional dialects, and it is frequently planted at household entrances, shrines, and boundary markers as a symbol of vitality, protection, and ancestral connection. In traditional medicine systems of Nigeria, Benin, Cameroon, and Ghana, healers have long employed the stem bark, leaves, and roots to treat epilepsy and convulsions, fevers, inflammatory conditions, bacterial infections, malaria, and liver diseases, with preparations transmitted orally across generations of traditional practitioners. Documented ethnobotanical surveys in Benin record specific use of the leaves for malaria and liver pathology, while bark preparations are more commonly associated with neurological and anti-infective applications. The tree's sacred status has historically protected it from over-harvesting in some regions, and its integration into both domestic and ritual contexts has sustained its availability as a medicinal resource throughout sub-Saharan Africa.

Health Benefits

- **Anticonvulsant and Neuroprotective Potential**: Traditional application in treating convulsions and epilepsy is supported by the presence of terpenes and flavonoids known to modulate neuronal excitability, though direct mechanistic evidence in seizure models for this species remains limited to ethnopharmacological records.
- **Anti-inflammatory Activity**: Humulene (16.85%) and Caryophyllene (7.51%) identified by GC-MS in ethanol stem bark extracts are sesquiterpenes with established cyclooxygenase and cytokine pathway inhibitory properties, contributing to the plant's traditional use in wound healing and inflammatory conditions.
- **Antioxidant Defense**: Phenolic compounds comprising approximately 35% of leaf composition, equivalent to 0.007 mg/ml catechin, inhibit beta-carotene bleaching and reduce ferric ions in a concentration-dependent manner, with peak antioxidant activity recorded at 4% at 40 minutes in assay conditions.
- **Antimicrobial Action**: Methanolic leaf extracts exhibit MIC values of 1.563 mg/ml against E. coli and Klebsiella spp., 3.125 mg/ml against Pseudomonas aeruginosa, Staphylococcus aureus, and Salmonella typhi, and a minimum bactericidal concentration (MBC) of 0.39 mg/ml against E. coli and S. aureus, supporting traditional use in treating bacterial infections.
- **Hepatoprotective Effects**: Ethnobotanical reports from Benin document use of leaves for liver diseases, and the presence of flavonoids, polyphenols, and stigmasterol (9.64% in methanolic leaf extracts) aligns with known hepatoprotective phytochemical profiles that reduce oxidative hepatocellular damage.
- **Analgesic and Anti-nociceptive Properties**: In vivo preclinical studies using Newbouldia laevis-loaded lipid microdispersions have demonstrated analgesic and anti-nociceptive effects, suggesting that bioactive delivery systems may enhance efficacy of the plant's pain-modulating constituents.
- **Antidiabetic and Cardioprotective Support**: Cardiac glycosides and steroidal compounds identified in methanolic leaf extracts, alongside the fatty acid profile including Linoleic acid (15.35%) and Oleic acid (14.68%), point to mechanisms relevant to glycemic regulation and cardiovascular lipid management as used in traditional African medicine systems.

How It Works

Humulene and Caryophyllene, the dominant sesquiterpenes in Newbouldia laevis ethanol stem bark extract, are known to inhibit pro-inflammatory mediators by suppressing NF-κB pathway activation and reducing prostaglandin synthesis via cyclooxygenase modulation, which underlies the plant's anti-inflammatory and putative anticonvulsant applications. Phenolic compounds and flavonoids in leaf extracts exert antioxidant effects through direct hydrogen atom donation and electron transfer mechanisms, evidenced by ferric-reducing antioxidant power (FRAP) assays and beta-carotene bleaching inhibition tests conducted at concentrations of 0.012–0.016 mg/ml. Antimicrobial activity is attributed to membrane-disrupting terpenes and polyphenols that compromise bacterial cell wall integrity, as reflected in the MIC and MBC data against gram-negative and gram-positive pathogens. Cardiac glycosides and stigmasterol may interact with Na⁺/K⁺-ATPase pumps and steroid hormone receptors respectively, though specific receptor-binding affinities or Ki values for Newbouldia laevis constituents have not been formally characterized in published molecular docking or radioligand binding studies.

Scientific Research

The current body of evidence for Newbouldia laevis is limited entirely to in vitro antimicrobial and antioxidant assays and a small number of preclinical in vivo animal studies; no randomized controlled trials or human clinical studies have been published as of the available literature. GC-MS phytochemical profiling studies of ethanol stem bark extracts have quantified 36 compounds totaling 96.57% relative abundance, providing a chemical foundation for bioactivity hypotheses, but these characterization studies are not interventional in design. Antimicrobial studies using methanolic leaf extracts report MIC values between 31.2 and 3125 μg/ml across multiple bacterial strains, with outcomes indicating moderate but not superior antimicrobial potency compared to reference antibiotics and comparator plants tested in parallel. The evidence base is best classified as preliminary, largely reliant on traditional use validation and in vitro screens, with no published Phase I, II, or III clinical trial data to establish pharmacokinetics, therapeutic dosing windows, or efficacy in human populations for any indication.

Clinical Summary

No clinical trials involving human participants have been identified for Newbouldia laevis in the context of epilepsy, convulsions, or any other indication, meaning clinical summary conclusions cannot be drawn from controlled human data. Preclinical findings include analgesic effects in animal models using lipid microdispersion delivery systems and concentration-dependent antioxidant activity confirmed by standardized chemical assays, which provide preliminary pharmacological plausibility. The MIC and MBC data from in vitro antimicrobial studies represent the most quantified outcomes available, showing efficacy at low milligram-per-milliliter concentrations against common bacterial pathogens, though these do not translate directly to clinical dosing recommendations. Confidence in therapeutic outcomes remains low pending well-designed animal epilepsy models, dose-escalation safety studies, and ultimately randomized human trials.

Nutritional Profile

Newbouldia laevis leaf and bark extracts are rich in bioactive phytochemicals rather than conventional macronutrients. Fatty acids in methanolic leaf extracts include Linoleic acid (9,12-Octadecadienoic acid, ~15.35%), Oleic acid (~14.68%), and Linoleic acid ethyl ester (~9.37% in bark), contributing polyunsaturated and monounsaturated fatty acid content relevant to membrane health and anti-inflammatory precursor availability. Phytosterols are represented by Stigmasterol (~9.64% in leaf extract), which competes with dietary cholesterol absorption. The phenolic fraction constitutes approximately 35% of leaf composition with a total phenolic content equivalent to 0.007 mg/ml catechin standard, indicating moderate but relevant antioxidant phytochemical density. Additional secondary metabolites include alkaloids, tannins, saponins, anthocyanins, coumarins, terpenoids, and cardiac glycosides; bioavailability of these compounds from traditional aqueous or ethanol preparations has not been formally quantified through pharmacokinetic studies.

Preparation & Dosage

- **Decoction (Traditional)**: Stem bark or leaves boiled in water for 15–30 minutes; traditionally consumed as a warm tea in unspecified volumes, commonly used across West Africa for seizures, fever, and infections.
- **Maceration/Cold Infusion (Traditional)**: Crushed leaves or bark soaked in cold water or palm wine overnight; filtered and consumed orally, sometimes applied topically to wounds.
- **Ethanol/Methanolic Extract (Research Use)**: In vitro and preclinical studies employed concentrations of 0.012–0.016 mg/ml for antioxidant assays and 1.563–3.125 mg/ml for antimicrobial screening; these concentrations are not directly translatable to human dosing.
- **Lipid Microdispersion (Experimental Delivery)**: Newbouldia laevis-loaded lipid microdispersions have been investigated in animal models for enhanced analgesic bioavailability; no standardized formulation or human dose has been established.
- **Standardization**: No commercial standardized extract with defined marker compound percentage is currently available; phytochemical standardization to Humulene, Caryophyllene, or total phenolics would be necessary before therapeutic dose ranges can be validated.
- **Timing and Route**: Traditional use is predominantly oral for systemic effects and topical for dermatological and wound-care indications; no pharmacokinetic data exist to guide dosing frequency or optimal administration timing.

Synergy & Pairings

In traditional African ethnomedicine, Newbouldia laevis is frequently used in polyherbal formulations alongside antimalarial plants such as Azadirachta indica (neem) and Morinda lucida, where overlapping phenolic and terpenoid profiles may produce additive or synergistic antimicrobial and anti-inflammatory effects through complementary free radical scavenging pathways. The combination of Humulene and Caryophyllene with dietary omega-3 fatty acids may enhance anti-inflammatory outcomes by simultaneously inhibiting arachidonic acid-derived eicosanoid production and activating CB2 cannabinoid receptors, a mechanism documented for Caryophyllene in isolation. Co-administration with antioxidant-rich botanical partners such as Moringa oleifera, which contributes isothiocyanates and quercetin, could amplify the ferric-reducing and beta-carotene-protective antioxidant capacity observed in Newbouldia laevis leaf extracts, though no formal interaction or combination study has been conducted.

Safety & Interactions

Formal clinical safety data for Newbouldia laevis are absent from the published literature, and no maximum tolerated dose, NOAEL, or established safe upper limit has been defined for any human population. A preliminary cytotoxicity screen of leaf extract using the brine shrimp lethality assay suggested low acute toxicity potential, but this model has limited predictive value for chronic human toxicity, drug interactions, or organ-specific adverse effects. The presence of cardiac glycosides in leaf extracts raises a theoretical concern for pharmacodynamic interactions with cardiac medications, particularly digoxin and other Na⁺/K⁺-ATPase inhibitors, and the anticoagulant or platelet-modifying potential of flavonoids and saponins warrants caution in patients on anticoagulant or antiplatelet therapy. Use during pregnancy and lactation is not recommended given the absence of safety data and the known uterotonic and hormonal activity of some steroidal and alkaloidal plant constituents; traditional use should not be extrapolated to confirm safety in these populations without controlled investigation.